Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Feb;132(3):297-305.
doi: 10.1111/1471-0528.17991. Epub 2024 Nov 13.

The Efficacy of Botulinum Toxin A Injection in Pelvic Floor Muscles in Chronic Pelvic Pain Patients: A Double-Blinded Randomised Controlled Trial

Melle A Spruijt  1   2 , Wenche M Klerkx  2 , Kim Notten  1 , Hugo van Eijndhoven  3 , Leonie Speksnijder  4 , Manon H Kerkhof  4   5 , Kirsten B Kluivers  1
Affiliations
Randomized Controlled Trial

The Efficacy of Botulinum Toxin A Injection in Pelvic Floor Muscles in Chronic Pelvic Pain Patients: A Double-Blinded Randomised Controlled Trial

Melle A Spruijt et al. BJOG. 2025 Feb.

Abstract

Objective: To evaluate and compare the efficacy and safety of Botulinum Toxin A (BTA) injections versus placebo injections, combined with pelvic floor muscle therapy (PFMT), in women with chronic pelvic pain (CPP).

Design: Randomised, double-blinded clinical trial (January 2020-April 2023).

Setting: This multicentre study was conducted at four hospitals in the Netherlands.

Population and sample: Ninety-four women with CPP and increased pelvic floor muscle tone despite previous PFMT, were enrolled.

Methods: Participants received either BTA injections (100 units) or placebo injections into the pelvic floor muscle, followed by four PFMT sessions.

Main outcomes and measures: Primary outcomes included the number of women with at least a 33% reduction in pain and those reporting (very) much improvement of their pain. Secondary outcomes covered quality of life and pelvic floor function. Follow-up visits were scheduled at 4, 8, 12, and 26 weeks post-treatment. Mixed models for repeated measurements were used for analysis.

Results: A 33% reduction or more in average pain score was reported by 15 participants (33%) after BTA treatment and 9 participants (20%) after placebo treatment (odd ratio placebo/BTA 1.88; 95% CI 0.72-4.90, p = 0.19). In both groups, 8 women (17%) reported their improvement as (very) much better (odd ratio placebo/BTA 0.947; 95% CI 0.32-2.80, p = 0.92). Pelvic floor resting activity decreased significantly after BTA treatment compared to placebo (p = 0.001).

Conclusion: The results from this study do not support the use of BTA injections in the management of CPP in women.

Keywords: botulinum toxin A; chronic pain; pelvic floor muscle; pelvic pain; physical therapy.

PubMed Disclaimer

Conflict of interest statement

The Botulinum toxin A was provided by Allergan/Abbvie (unrestricted).

Figures

FIGURE 1
FIGURE 1
Participant flow.
FIGURE 2
FIGURE 2
(a) Average pain score past 4 weeks; (b) Pelvic floor resting activity measure by MAPLe (μV).
See this image and copyright information in PMC

References

    1. Doggweiler R., Whitmore K. E., Meijlink J. M., et al., “A Standard for Terminology in Chronic Pelvic Pain Syndromes: A Report From the Chronic Pelvic Pain Working Group of the International Continence Society,” Neurourology and Urodynamics 36, no. 4 (2017): 984–1008, 10.1002/nau.23072. - DOI - PubMed
    1. Mathias S. D., Kuppermann M., Liberman R. F., Lipschutz R. C., and Steege J. F., “Chronic Pelvic Pain: Prevalence, Health‐Related Quality of Life, and Economic Correlates,” Obstetrics and Gynecology 87, no. 3 (1996): 321–327, 10.1016/0029-7844(95)00458-0. - DOI - PubMed
    1. Ahangari A., “Prevalence of Chronic Pelvic Pain Among Women: An Updated Review,” Pain Physician 17 (2014): 141–147. - PubMed
    1. Frawley H., Shelly B., Morin M., et al., “An International Continence Society (ICS) Report on the Terminology for Pelvic Floor Muscle Assessment,” Neurourology and Urodynamics 40, no. 5 (2021): 1217–1260, 10.1002/nau.24658. - DOI - PubMed
    1. Aoki K. R., “Evidence for Antinociceptive Activity of Botulinum Toxin Type A in Pain Management,” Headache 43, no. 1 (2003): S9–S15. - PubMed

Publication types

Substances